GSK PLC-SPON ADR (GSK) Fundamental Analysis & Valuation

NYSE:GSK • US37733W2044

54.51 USD
-0.76 (-1.38%)
At close: Mar 6, 2026
54.51 USD
0 (0%)
After Hours: 3/6/2026, 8:23:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GSK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

GSK gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. GSK scores excellent on profitability, but there are some minor concerns on its financial health. GSK scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

8

1. GSK Profitability Analysis

1.1 Basic Checks

  • In the past year GSK was profitable.
  • In the past year GSK had a positive cash flow from operations.
  • Each year in the past 5 years GSK has been profitable.
  • In the past 5 years GSK always reported a positive cash flow from operatings.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.35%, GSK belongs to the top of the industry, outperforming 90.67% of the companies in the same industry.
  • The Return On Equity of GSK (34.90%) is better than 95.34% of its industry peers.
  • GSK has a Return On Invested Capital of 19.19%. This is amongst the best in the industry. GSK outperforms 95.34% of its industry peers.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • GSK's Profit Margin of 17.50% is amongst the best of the industry. GSK outperforms 90.67% of its industry peers.
  • In the last couple of years the Profit Margin of GSK has declined.
  • With an excellent Operating Margin value of 27.47%, GSK belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
  • GSK's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 72.67%, GSK belongs to the best of the industry, outperforming 80.83% of the companies in the same industry.
  • In the last couple of years the Gross Margin of GSK has remained more or less at the same level.
Industry RankSector Rank
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. GSK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GSK is creating value.
  • There is no outstanding debt for GSK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 2.32 indicates that GSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GSK has a better Altman-Z score (2.32) than 65.80% of its industry peers.
  • GSK has a debt to FCF ratio of 3.73. This is a good value and a sign of high solvency as GSK would need 3.73 years to pay back of all of its debts.
  • GSK has a better Debt to FCF ratio (3.73) than 88.60% of its industry peers.
  • GSK has a Debt/Equity ratio of 0.90. This is a neutral value indicating GSK is somewhat dependend on debt financing.
  • GSK has a Debt to Equity ratio of 0.90. This is in the lower half of the industry: GSK underperforms 70.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.32
ROIC/WACC2.1
WACC9.15%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that GSK may have some problems paying its short term obligations.
  • GSK has a worse Current ratio (0.82) than 86.53% of its industry peers.
  • A Quick Ratio of 0.54 indicates that GSK may have some problems paying its short term obligations.
  • GSK's Quick ratio of 0.54 is on the low side compared to the rest of the industry. GSK is outperformed by 87.05% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GSK Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.84% over the past year.
  • The Earnings Per Share has been growing slightly by 3.55% on average over the past years.
  • The Revenue has been growing slightly by 4.11% in the past year.
  • Measured over the past years, GSK shows a small growth in Revenue. The Revenue has been growing by 6.05% on average per year.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.00% on average over the next years.
  • GSK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.96% yearly.
EPS Next Y8.81%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
EPS Next 5Y5%
Revenue Next Year4.15%
Revenue Next 2Y4.52%
Revenue Next 3Y4.05%
Revenue Next 5Y2.96%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. GSK Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.65, the valuation of GSK can be described as very reasonable.
  • Based on the Price/Earnings ratio, GSK is valued cheaper than 88.60% of the companies in the same industry.
  • GSK is valuated cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • GSK is valuated reasonably with a Price/Forward Earnings ratio of 10.71.
  • GSK's Price/Forward Earnings ratio is rather cheap when compared to the industry. GSK is cheaper than 88.08% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, GSK is valued rather cheaply.
Industry RankSector Rank
PE 11.65
Fwd PE 10.71
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 91.19% of the companies in the same industry are more expensive than GSK, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, GSK is valued cheaply inside the industry as 86.53% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.21
EV/EBITDA 7.63
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)1.32
PEG (5Y)3.28
EPS Next 2Y8.7%
EPS Next 3Y9.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. GSK Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.23%, GSK has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.68, GSK pays a better dividend. On top of this GSK pays more dividend than 94.82% of the companies listed in the same industry.
  • GSK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 3.23%

5.2 History

  • The dividend of GSK decreases each year by -9.84%.
  • GSK has paid a dividend for at least 10 years, which is a reliable track record.
  • The dividend of GSK decreased recently.
Dividend Growth(5Y)-9.84%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • GSK pays out 44.86% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK Fundamentals: All Metrics, Ratios and Statistics

GSK PLC-SPON ADR

NYSE:GSK (3/6/2026, 8:23:23 PM)

After market: 54.51 0 (0%)

54.51

-0.76 (-1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners43.55%
Inst Owner Change181.39%
Ins Owners0.1%
Ins Owner ChangeN/A
Market Cap109.38B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts70
Price Target54.76 (0.46%)
Short Float %0.67%
Short Ratio2.48
Dividend
Industry RankSector Rank
Dividend Yield 3.23%
Yearly Dividend1.63
Dividend Growth(5Y)-9.84%
DP44.86%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)8.36%
PT rev (3m)15.05%
EPS NQ rev (1m)-3.11%
EPS NQ rev (3m)-5.81%
EPS NY rev (1m)0.13%
EPS NY rev (3m)0.57%
Revenue NQ rev (1m)-0.83%
Revenue NQ rev (3m)-1.31%
Revenue NY rev (1m)-0.9%
Revenue NY rev (3m)-0.43%
Valuation
Industry RankSector Rank
PE 11.65
Fwd PE 10.71
P/S 2.51
P/FCF 17.21
P/OCF 10.58
P/B 5
P/tB N/A
EV/EBITDA 7.63
EPS(TTM)4.68
EY8.59%
EPS(NY)5.09
Fwd EY9.34%
FCF(TTM)3.17
FCFY5.81%
OCF(TTM)5.15
OCFY9.46%
SpS21.75
BVpS10.91
TBVpS-4.92
PEG (NY)1.32
PEG (5Y)3.28
Graham Number33.89
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 22.59%
ROIC 19.19%
ROICexc 20.98%
ROICexgc 60.71%
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.15
Cap/Depr 79.01%
Cap/Sales 9.14%
Interest Coverage 13.22
Cash Conversion 60.7%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.32
F-Score9
WACC9.15%
ROIC/WACC2.1
Cap/Depr(3y)99.36%
Cap/Depr(5y)105.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.81%
EPS Next 2Y8.7%
EPS Next 3Y9.89%
EPS Next 5Y5%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year4.15%
Revenue Next 2Y4.52%
Revenue Next 3Y4.05%
Revenue Next 5Y2.96%
EBIT growth 1Y15.03%
EBIT growth 3Y2.25%
EBIT growth 5Y8.41%
EBIT Next Year28.68%
EBIT Next 3Y11.85%
EBIT Next 5Y7.68%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


How profitable is GSK PLC-SPON ADR (GSK) stock?

GSK PLC-SPON ADR (GSK) has a profitability rating of 8 / 10.


What is the financial health of GSK PLC-SPON ADR (GSK) stock?

The financial health rating of GSK PLC-SPON ADR (GSK) is 4 / 10.


What is the earnings growth outlook for GSK PLC-SPON ADR?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.81% in the next year.